Literature DB >> 11809726

Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.

Natasha J Caplen1, J Paul Taylor, Victoria S Statham, Fumiaki Tanaka, Andrew Fire, Richard A Morgan.   

Abstract

RNA interference (RNAi) is a mechanism that appears to control unwanted gene expression in a wide range of species. In Drosophila, RNAi is most effectively induced by double-stranded RNAs (dsRNAs) of over approximately 80 nucleotides (nt) and in mammalian cells an RNAi-like inhibition of gene expression has been shown to be mediated by dsRNAs of approximately 21-23 nt. To test if RNAi can be used to specifically down-regulate a human disease-related transcript we have used Drosophila and human tissue culture models of the dominant genetic disorder spinobulbar muscular atrophy (SBMA). A variety of different dsRNAs were assessed for the ability to inhibit expression of transcripts that included a truncated human androgen receptor (ar) gene containing different CAG repeat lengths (16-112 repeats). In Drosophila cells, dsRNAs corresponding to non-repetitive sequences mediated a high degree of sequence-specific inhibition, whereas RNA duplexes containing CAG repeat tracts only induced gene-specific inhibition when flanking ar sequences were included; dsRNAs containing various lengths of CAG repeats plus ar sequences were unable to induce allele-specific interference. In mammalian cells we tested sequence-specific small dsRNAs of 22 nt; these rescued the toxicity and caspase-3 activation induced by plasmids expressing a transcript encoding an expanded polyglutamine tract. This study demonstrates the feasibility of targeting a transcript associated with an important group of genetic diseases by RNAi.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809726     DOI: 10.1093/hmg/11.2.175

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

Review 2.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

3.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

Review 4.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Post-transcriptional suppression of gene expression in Xenopus embryos by small interfering RNA.

Authors:  Yuan Zhou; Yick-Pang Ching; Kin Hang Kok; Hsiang-fu Kung; Dong-Yan Jin
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

Review 6.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

Review 7.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

8.  Trans-splicing in C. elegans generates the negative RNAi regulator ERI-6/7.

Authors:  Sylvia E J Fischer; Maurice D Butler; Qi Pan; Gary Ruvkun
Journal:  Nature       Date:  2008-09-10       Impact factor: 49.962

9.  Mouse Huntington's disease homolog mRNA levels: variation and allele effects.

Authors:  Karen T Dixon; Jamie A Cearley; Jesse M Hunter; Peter J Detloff
Journal:  Gene Expr       Date:  2004

10.  Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.

Authors:  Janine Scholefield; L Jacquie Greenberg; Marc S Weinberg; Patrick B Arbuthnot; Amr Abdelgany; Matthew J A Wood
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.